Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000

Front Matter....Pages i-xxii
Front Matter....Pages 1-1
What are the biochemical and physiological implications of the new genetic information?....Pages 3-14
The urease system of Helicobacter pylori ....Pages 15-24
The amphibiotic relationship of Helicobacter pylori and humans....Pages 25-30
 Helicobacter pylori is pathogenic flora....Pages 31-35
Disease-specific Helicobacter pylori virulence factors: the role of cagA, vacA, iceA, babA2 alone or in combination....Pages 37-42
Front Matter....Pages 43-43
Factors associated with disappearance of Helicobacter pylori in the West....Pages 45-51
Factors associated with disappearance of Helicobacter pylori in the Far East....Pages 53-56
Differences in prevalence of Helicobacter pylori and disease outcomes according to race/environmental factors in Southeast Asia....Pages 57-70
Front Matter....Pages 71-71
Infection with Helicobacter heilmannii (formerly Gastrospirillum horminis ): characterization, epidemiology and therapy....Pages 73-81
Hepatobiliary Helicobacters : recognized animal pathogens with suspected pathogenic potential in humans....Pages 83-104
Novel Helicobacter species in the intestine....Pages 105-112
Front Matter....Pages 113-113
Diagnosis of Helicobacter pylori infection: faecal antigen determination....Pages 115-122
Pitfalls in Helicobacter pylori diagnosis....Pages 123-138
Front Matter....Pages 139-139
Overview of immune and inflammatory changes due to Helicobacter infection....Pages 141-150
Interaction of Helicobacter pylori with gastric epithelium....Pages 151-154
 Helicobacter pylori and the epithelial barrier: role of oxidative injury....Pages 155-168
Immuno-inflammatory response to Helicobacter pylori in children....Pages 169-174
Severity and reversibility of mucosal inflammation in children and adolescents infected with Helicobacter pylori ....Pages 175-186
Elimination of Helicobacter pylori is dependent on a Th2 response....Pages 187-191
Elimination of Helicobacter pylori is not dependent on a Th2 cytokine response....Pages 193-195
Front Matter....Pages 139-139
The inflamatory activity in Helicobacter pylori infection is predominantly organism related....Pages 197-202
The inflammatory activity in Helicobacter pylori infection is predominantly host-related....Pages 203-209
Front Matter....Pages 211-211
 Helicobacter pylori gastritis — a global view....Pages 213-220
Unusual forms of gastric inflammation and their relationship to Helicobacter pylori infection....Pages 221-228
Can atrophic gastritis be diagnosed in the presence of Helicobacter pylori infection?....Pages 229-237
Mechanisms involved in gastric atrophy....Pages 239-247
Intestinal metaplasia: types, mechanisms of origin, and role in gastric cancer histogenesis....Pages 249-254
Long-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori -positive patients....Pages 255-267
Proton pump inhibitors do not accelerate the development of gastric atrophy in Helicobacter pylori gastritis....Pages 269-280
Autoimmune gastritis via mimicking does occur....Pages 281-287
Autoimmune gastritis and antigenic mimicking....Pages 289-293
Carditis and intestinal metaplasia of the cardia is reflux related....Pages 295-298
Carditis and cardia intestinal metaplasia are Helicobacter pylori -related....Pages 299-306
Is gastric metaplasia in Helicobacter pylori really gastric?....Pages 307-311
Front Matter....Pages 313-313
Extragastric manifestations of Helicobacter pylori — are they relevant?....Pages 315-326
Peptic ulcer disease — the transitional zones are important....Pages 327-338
What causes Helicobacter pylori -negative non-NSAID-related ulcers?....Pages 339-345
From the pump to the helix....Pages 347-372
Mechanisms involved in the development of hypochlorhydria and pangastritis in Helicobacter pylori infection....Pages 373-384
Effect of Helicobacter pylori infection on gastric acid control using proton pump inhibitors....Pages 385-390
Front Matter....Pages 313-313
Rebound acid hypersecretion after acid-suppressive therapy....Pages 391-396
Gastric consequences of proton pump inhibitor therapy and Helicobacter pylori eradication....Pages 397-408
Front Matter....Pages 409-409
Current concepts of dyspepsia: the role of the nervous system....Pages 411-420
How to explain outcome differences in dyspepsia studies....Pages 421-425
 Helicobacter pylori eradication for dyspepsia is clinically useful....Pages 427-433
Dyspepsia is no indication for Helicobacter pylori eradication....Pages 435-441
Role of Helicobacter pylori infection in NSAID-associated gastropathy....Pages 443-451
Role of Helicobacter pylori in NSAID gastrophy: can H. pylori infection be beneficial?....Pages 453-459
 Helicobacter pylori and non-steroidal anti-inflammatory drugs....Pages 461-466
Front Matter....Pages 467-467
The impact of a test-and-treat strategy for Helicobacter pylori : the United States perspective....Pages 469-473
Test-and-treat strategy in dyspepsia — the European perspective....Pages 475-482
The impact of the ‘test-and-treat’ strategies for Helicobacter pylori infection — an Asian perspective?....Pages 483-486
Front Matter....Pages 487-487
Rodent models for Helicobacter -induced gastric cancer....Pages 489-505
 Helicobacter pylori and gastric cancer: the risk is real....Pages 507-511
 Helicobacter pylori in gastric malignancy: role of oxidants, antioxidants and other co-factors....Pages 513-524
Gastric markers of pre-malignancy are not reversible....Pages 525-534
The case for the reversibility of gastric dysplasia/neoplasia....Pages 535-539
Evaluation of the long-term outcome of Helicobacter pylori -related gastric mucosa-associated lymphoid tissue (MALT) lymphoma....Pages 541-548
Front Matter....Pages 555-555
Current state-of-the-art management for Helicobacter pylori infection: global perspective....Pages 551-558
Guidelines for therapy of Helicobacter pylori infection — a world perspective....Pages 559-565
Front Matter....Pages 555-555
Bismuth triple and quadruple studies for Helicobacter pylori eradication in Canada....Pages 567-573
Approach to Helicobacter pylori infection in children....Pages 575-585
What role for clarithromycin in the treatment of Helicobacter pylori infection?....Pages 587-591
What is the role of bismuth in Helicobacter pylori antimicrobial resistance?....Pages 593-599
Risk factors for failure of Helicobacter pylori eradication therapy....Pages 601-607
Strategies for therapy failures: Choice of ‘back-up’ regimen determined by primary treatment for Helicobacter pylori infection....Pages 609-621
Quadruple should be first-line therapy for Helicobacter pylori infection....Pages 623-629
Quadruple therapy should be second-line treatment for Helicobacter pylori infection....Pages 631-635
 Helicobacter pylori infection: expectations for future therapy....Pages 637-642
A Helicobacter pylori vaccine is essential....Pages 643-651
Front Matter....Pages 653-653
The agenda for the microbiologist....Pages 655-662
The agenda for the immunologist....Pages 663-668
The agenda for the histopathologist....Pages 669-671
 Helicobacter infections in the new millennium: the challenge for the clinician....Pages 673-678
Back Matter....Pages 679-689